NSE filing, NSE: SATKARTAR. Summary written from the filing by ALFA Finder's alert engine.
Sat Kartar Life Ltd: key numbers
- Share price
- ₹126.50
- Market cap
- ₹199.8 Cr
- Revenue (annual)
- ₹200.7 Cr
- Net profit (annual)
- ₹17.10 Cr
- P/E (TTM)
- 11.7×Sector 47.2×
- Promoter holding
- 63.49%
- FII holding
- 0.77%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sat Kartar Life Ltd
All →Sat Kartar Life Capacity Expansion: ₹1 Cr Investment
Sat Kartar Life proposes a 25-bed Ayurveda hospital-cum-therapy centre in Lucknow at ₹1 Crore investment. Expected operational by February 2027 as part of its healthcare network expansion.
- Value
- ₹1.00 Cr
- Execution
- Expected operational by February 2027
- hospital beds
- 25 beds
Sat Kartar Life Earnings Call Transcript: Key Takeaways
Sat Kartar Life is pivoting from pure Ayurveda products to an integrated healthcare model, showing strong revenue growth but scaling back prior top-line guidance to prioritize margins.
- Call
- Guides 32% growth
Sat Kartar Life H1 FY27 Results: Net Profit ₹9.2 Cr, Up 26.0% YoY
Sat Kartar Life Ltd reported revenue from operations of ₹113.9 Cr (+26.4% YoY) and net profit of ₹9.2 Cr (+26.0% YoY) for H1 FY27.
- Key figure
- Net profit ₹9.2 Cr · +26.0% YoY
Sat Kartar Life Investor Presentation: Key Takeaways
H1 FY27 deck discloses no revenue, PAT or EBITDA figures. Balance sheet is debt-free with ₹18.7 Cr net cash. Growth is hospital-led: 30-bed Delhi unit at breakeven, 300 beds targeted by FY27-end.
Sat Kartar Life Results Update
Sat Kartar Life Limited reported H1 FY27 revenue growth of 26% and EBITDA growth of 48% via press release. Its first Ayurveda hospital reached operating breakeven.
Sat Kartar Life Other Announcement
Sat Kartar Life filed CARE Ratings' IPO proceeds monitoring report for half year ended September 2026. It shows nil deviation from objects, so no new event occurred.
Other convertible warrants announcements
All →Dev Accelerator Convertible Warrants
Dev Accelerator allotted 33,33,330 equity shares to three promoters at Rs.45 each on conversion of warrants. The balance subscription of Rs.11.25 Crore was received.
- Value
- ₹11.25 Cr
Emkay Global Financial Services Convertible Warrants
Emkay Global received NSE and BSE trading approval for 1,00,000 equity shares issued to promoter Prakash Kacholia on conversion of preferential warrants. Shares are admitted to dealings from 4 November 2026, subject to an 18-month lock-in.
AUDROC Convertible Warrants
Audroc submitted the first Monitoring Agency Report for the quarter ended 30 September 2026 on its preferential issue of warrants. Rs.70.39 crore of the Rs.80.00 crore proposed issue had been received, with no deviation from objects.
- Value
- ₹70.39 Cr
U Y Fincorp Convertible Warrants
U. Y. Fincorp seeks EOGM approval on November 25, 2026 to issue 2,45,90,000 warrants worth Rs 59.9996 Crore to promoters. Warrants convert into equity within 18 months.
- Value
- ₹60.00 Cr
Emrock Corporation Convertible Warrants
Emrock allotted 74.35 lakh equity shares on conversion of warrants, receiving Rs.6.13 Crore balance subscription. Listing and trading approvals for the new shares are pending.
- Value
- ₹6.13 Cr
Krsnaa Diagnostics Convertible Warrants
Krsnaa's auditor certified upfront consideration for 16.21 lakh promoter warrants at Rs.566 each, totalling Rs.91.75 Crore issue value. Certificate confirms upfront money came directly from allottees' accounts.
- Value
- ₹91.75 Cr